NDAORALTABLET
Approved
Mar 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENOVID is an oral contraceptive tablet combining mestranol (estrogen) and norethynodrel (progestin), approved in 1961 as one of the first combined oral contraceptives. It prevents pregnancy through hormonal suppression of ovulation. This product represents a foundational therapy class that transformed women's reproductive health and family planning.
LOE Approaching
Declining
Brand is in late-stage lifecycle with minimal active development; commercial teams are likely small and focused on market defense rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ENOVID represents a career in product sunset management rather than growth or innovation; roles would focus on compliance, generic competition defense, and eventual product discontinuation. This is not a position for professionals seeking dynamic career trajectories or cutting-edge pharmaceutical development exposure.
Brand Manager (Legacy Support)Regulatory Affairs (Compliance)
Worked on ENOVID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.